In a meta-analysis by Loman et al. [30], who analyzed both pre- and probiotics in NAFLD patients, results were similar: microbial-based therapies favored an increased secretion of hepatic enzymes (ALT (MD) = −6.9 U/L, AST (MD) = −4.6 U/L, γ-GTP (MD) = −7.9 U/L, p < 0.001). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.